IL17A and spondyloarthropathy: In addition to DKK1, the dual blockade of TNF and IL-17A was reported to ameliorate inflammation and structural damage in a rat model of spondyloarthritis [8], suggesting that TNF and IL-17A have pathogenic effects on bone metabolism.